Josh Disbrow stands at the helm of Aytu BioPharma as its Chief Executive Officer and Board Director, a company he co-founded in 2015. His visionary leadership propelled Aytu BioPharma to a remarkable feat – securing a coveted NASDAQ listing in 2017, all while steering the company to exceed $100 million in annual revenues within just seven years. In addition to orchestrating the company's impressive growth trajectory, Josh's strategic acumen drove the completion of four significant company acquisitions in under four years. A testament to his influential prowess, Josh extends his leadership to Zynex, Inc., a publicly-listed medical device firm specializing in electrotherapy and pain management. Here, he is a pivotal board member, prominently chairing the Nominating and Governance Committee, reinforcing his unwavering dedication to upholding strong corporate governance practices. Josh's career is an odyssey marked by milestones. Commencing as a sales representative at Glaxo Wellcome, his journey encompassed pivotal commercial and leadership roles at Cyberonics, LipoScience, Arbor Pharmaceuticals, and Ampio Pharmaceuticals. Underpinning his industry accomplishments is a robust academic foundation. A Bachelor of Science in Management with honors from North Carolina State University set the stage, further fortified by a Master of Business Administration from Wake Forest University School of Business. However, Josh's story transcends the professional realm, exemplifying an unwavering commitment to philanthropy. Josh, alongside his wife, champions charitable causes, notably supporting Invest-in-Kids and their annual Jane-A-Thon fundraiser, a beacon of hope for children and young families across Colorado. Their altruism extends to local churches and several charitable organizations. This benevolent spirit found manifestation in a mission trip to Puerto Penasco, Mexico, where they constructed a home for a deserving family. This service ethos permeates Aytu BioPharma, as Josh empowers employees with a Volunteer Day, allowing them to contribute to causes close to their hearts.